At least 18 children in Uzbekistan have unfortunately passed away after they consumed Doc-1 Max – a cough syrup manufactured by India-based Marion Biotech. This tragedy follows the laboratory tests revealing the presence of ethylene glycol, a toxin, in the syrup.
It has also been revealed that the cough syrup was used as an anti-cold remedy at home, prompting the health ministry in Uzbekistan to issue a statement about the incident.
This is not the first time India-made cough syrups have been in question – earlier in the year, a whopping 70 children from Gambia met untimely deaths due to syrups from the Haryana-based Maiden Pharmaceuticals.
These reports of serious consequences as a result of using Indian-made cough syrups have definitely caused alarm and it is yet to be seen what actions will be taken to prevent any further tragedies from unfolding.
Conclusion: The tragic incident involving the deaths of 18 children in Uzbekistan after taking an India-manufactured cough syrup has highlighted the need for intensified controls for the production and distribution of medicated syrups. Rigorous safety checks must be put in place to ascertain the safety of cough syrup and similar products before it reaches consumers. Indian pharmaceutical companies must also review their practices with regard to manufacturing and quality control and ensure their products maintain the highest standards of safety and efficacy for protecting the health and well-being of citizens globally. Therefore, it is a call for much-needed action and rectification of any pitfalls in production protocols to ensure similar cases will not be repeated in the future.